

Improving outcomes of schizophrenia with long-acting antipsychotic treatment: impact on patients and carers

Scientific committee: István Bitter, Hungary; Silvana Galderisi, Italy

Chair: István Bitter, Hungary

Co-Chair: Anders Fink-Jensen, Denmark

Saturday 7th September 2019, 14:45–16:15

Bella Centre Copenhagen, Auditorium 15, Copenhagen, Denmark

14:45 Welcome and introduction

István Bitter, Hungary

14:55 Clinical benefits of the pharmacological characteristics of long-acting antipsychotic treatment

David Taylor, UK

15:15 Comprehensive long term treatment programmes for improving schizophrenia outcomes

Silvana Galderisi, Italy

15:35 Treating early phase schizophrenia: can we do better?

Robin Emsley, South Africa

15:55 Panel discussion with all speakers (general Q&A session)

István Bitter, Hungary and Anders Fink-Jensen, Denmark

16:10 Closing remarks

Anders Fink-Jensen, Denmark

The European Accreditation Committee in CNS (EACIC) has granted 2 CME credits to this satellite symposium. To obtain your CME credits, please fill out the evaluation form on www.eacic.eu

With the educational financial support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA.

Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium

Date of preparation: August 2019 EM-07161



Donna Williams, *Discovery*

An autistic artist, author and renowned autism advocate, Donna passed away from cancer in 2017

**Satellite symposium
on the occasion of the
32nd ECNP Congress**

Copenhagen, Denmark
7–10th September 2019